Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Malignant rhabdoid tumor of the liver presented with initial tumor rupture.
Kachanov D, Teleshova M, Kim E, Dobrenkov K, Moiseenko R, Usychkina A, Filin A, Semenkov A, Mitrofanova A, Konovalov D, Shamanskaya T, Novichkova G, Varfolomeeva S. Kachanov D, et al. Among authors: dobrenkov k. Cancer Genet. 2014 Sep;207(9):412-4. doi: 10.1016/j.cancergen.2014.04.006. Epub 2014 Apr 21. Cancer Genet. 2014. PMID: 24894493
Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy.
Guelen L, Fischmann TO, Wong J, Mauze S, Guadagnoli M, Bąbała N, Wagenaars J, Juan V, Rosen D, Prosise W, Habraken M, Lodewijks I, Gu D, Stammen-Vogelzangs J, Yu Y, Baker J, Lutje Hulsik D, Driessen-Engels L, Malashock D, Kreijtz J, Bertens A, de Vries E, Bovens A, Bramer A, Zhang Y, Wnek R, Troth S, Chartash E, Dobrenkov K, Sadekova S, van Elsas A, Cheung JK, Fayadat-Dilman L, Borst J, Beebe AM, Van Eenennaam H. Guelen L, et al. Among authors: dobrenkov k. J Immunother Cancer. 2022 Sep;10(9):e005049. doi: 10.1136/jitc-2022-005049. J Immunother Cancer. 2022. PMID: 36100308 Free PMC article.
Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies.
Moreno V, Calvo E, Middleton MR, Barlesi F, Gaudy-Marqueste C, Italiano A, Romano E, Marabelle A, Chartash E, Dobrenkov K, Zhou H, Connors EC, Zhang Y, Wermke M. Moreno V, et al. Among authors: dobrenkov k. Cancer Immunol Immunother. 2022 Dec;71(12):2985-2998. doi: 10.1007/s00262-022-03191-8. Epub 2022 May 21. Cancer Immunol Immunother. 2022. PMID: 35596791 Free PMC article. Clinical Trial.
First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors.
Geva R, Voskoboynik M, Dobrenkov K, Mayawala K, Gwo J, Wnek R, Chartash E, Long GV. Geva R, et al. Among authors: dobrenkov k. Cancer. 2020 Nov 15;126(22):4926-4935. doi: 10.1002/cncr.33133. Epub 2020 Aug 18. Cancer. 2020. PMID: 32809217 Free article. Clinical Trial.
20 results